FDA approves sotatercept, now Winrevair, to treat PAH in adults
The U.S. Food and Drug Administration (FDA) has approved the under-the-skin injection therapy sotatercept-csrk — to be marketed under the brand name Winrevair — to treat adults with pulmonary arterial hypertension (PAH). The now-approved treatment is expected to be available for dispensing by select U.S. specialty pharmacies by the…